Table 1

Baseline characteristics in 18 646 patients with type 2 diabetes, aged 30–80 years

AspirinNo aspirinp Value*p Value**
Numbers460814038
Age (years)65.2±8.361.4±9.8<0.0010.85
Diabetes duration (years)8.1±6.56.6±6.0<0.0010.11
HbA1c, % (mmol/mol)7.1±1.1 (54)7.0±1.2 (53)0.030.035
Systolic BP (mm Hg)142±16139±16<0.0010.41
BMI (kg/m2)29.8±5.029.6±5.30.020.68
Total cholesterol (mmol/l)4.80±0.925.06±0.97<0.001
HDL cholesterol (mmol/l)1.36±0.401.38±0.410.003
Ratio total:HDL cholesterol3.77±1.163.93±1.27<0.0010.07
Male gender56.155.00.20.005
Smoking15.015.50.30.60
Albuminuria >20 µg/min24.218.5<0.0010.90
Previous hospitalisation4.54.40.80.68
Hypoglycaemic treatment
 Oral agents only46.244.50.0040.51
 Oral agents and insulin20.112.3<0.0010.72
 Insulin only12.614.00.020.44
ACE inhibitors32.818.8<0.0010.70
ACE inhibitors+diuretics5.32.6<0.0010.56
ACE inhibitors+Ca antagonists0.040.020.40.04
AT2 antagonists15.29.9<0.0010.91
AT2 antagonists+diuretics9.85.2<0.0010.40
Ca antagonists26.314.2<0.0010.23
β Receptor blockers38.321.7<0.0010.29
Diuretics26.615.0<0.0010.35
α Receptor blockers1.50.7<0.0010.68
Statins55.729.1<0.0010.19
Other lipid lowering drugs2.51.6<0.0010.39
Oestrogen5.25.40.60.42
Multidose dispensation1.10.80.070.35
  • Means±SD and frequencies (%) are given.

  • *Significance using t test or χ2 test.

  • **Significance using GLM after adjustment by stratification with a propensity score.

  • BMI, body mass index; BP, blood pressure; GLM, general linear modelling; HDL, high-density lipoprotein.